|
|
Volumn 29, Issue 22, 2011, Pages 3105-
|
|
Immunotherapy for glioblastoma: The devil is in the details
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANCER VACCINE;
EPIDERMAL GROWTH FACTOR RECEPTOR;
TEMOZOLOMIDE;
ALKYLATING AGENT;
DACARBAZINE;
DRUG DERIVATIVE;
EPIDERMAL GROWTH FACTOR RECEPTOR VIII;
CANCER IMMUNIZATION;
CANCER IMMUNOTHERAPY;
CANCER RADIOTHERAPY;
CLINICAL PROTOCOL;
DRUG EFFICACY;
DRUG TARGETING;
GENE MUTATION;
GLIOBLASTOMA;
HUMAN;
LETTER;
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROTEIN EXPRESSION;
SURVIVAL RATE;
TREATMENT OUTCOME;
ADJUVANT CHEMOTHERAPY;
ADJUVANT THERAPY;
BRAIN TUMOR;
DRUG EFFECT;
GENETICS;
IMMUNOLOGY;
MUTATION;
NOTE;
RADIATION EXPOSURE;
SURVIVAL;
ANTINEOPLASTIC AGENTS, ALKYLATING;
BRAIN NEOPLASMS;
CANCER VACCINES;
CHEMOTHERAPY, ADJUVANT;
CLINICAL TRIALS, PHASE II AS TOPIC;
DACARBAZINE;
GLIOBLASTOMA;
HUMANS;
MUTATION;
RADIOTHERAPY, ADJUVANT;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
SURVIVAL ANALYSIS;
|
|
EID: 80051605627
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2011.34.9019 Document Type: Letter |
|
Times cited : (11)
|
|
References (4)
|
